诺诚健华2024年净亏损收窄30.20% 公司:目前没有缩减研发团队计划

每日经济新闻
29 Mar

每经记者 林姿辰 每经编辑 董兴生近日,诺诚健华(SH688428)发布2024年年报,其核心产品奥布替尼在上市4年后,终于迈过了年销10亿元的大关。而且,公司预计奥布替尼一线治疗慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)的适应症将于2025年获批,第二款商业化产品Tafasitamab(坦昔妥单抗)将于今年上半年在国内获批。《每日经济新闻》记者注意到,随着研发管线接近商业化,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10